AD-214 is under clinical development by AdAlta and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase I drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AD-214’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AD-214 overview

AD-214 is under development for the treatment of interstitial lung disease, fibrotic diseases including idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, wet macular degeneration, kidney fibrosis, eye fibrosis, interstitial lung disease, hypertrophic scars, chronic kidney disease, collagen-vascular disease (CVD), fibrotic non-specific interstitial pneumonia (fNSIP) or chronic fibrosing hypersensitivity pneumonitis (cHP) and unspecified cancer. It is an Fc-Fusion protein containing two AD-114 i-body molecules at the front end that binds with CXCR4 and an Fc Fragment in the tail region. It is administered via parenteral, intravenous and inhalational route. The therapeutic candidate is developed based on i-body technology.

AdAlta overview

AdAlta formerly AdAlta, is a biotechnology company. It discovers and develops a new class of protein therapeutics for use in treating serious diseases. The company’s lead i-body drug candidate, AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules that bind to the human target CXCR4 and demonstrates anti-fibrotic effects in treating a type of fibrosis of the lung, known as idiopathic pulmonary fibrosis (IPF). Its i-body products are developed using proprietary technology platform that delivers specific biologics and affinity against a variety of therapeutic and diagnostic targets such as cell surface, membrane-spanning and complex proteins. AdAlta utilizes the i-body technology to create a pipeline of new drugs for treating fibrotic diseases. The company collaborates with various pharmaceutical and biotech companies in Australia. AdAlta is headquartered in Melbourne, Victoria, Australia.

For a complete picture of AD-214’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.